Akari Therapeutics Gestione

Gestione criteri di controllo 2/4

Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.

Informazioni chiave

Samir Patel

Amministratore delegato

US$9.8k

Compenso totale

Percentuale dello stipendio del CEO	n/a
Mandato del CEO	less than a year
Proprietà del CEO	20.5%
Durata media del management	Nessun dato
Durata media del Consiglio di amministrazione	4.1yrs

Aggiornamenti recenti sulla gestione

Recent updates

AMMINISTRATORE DELEGATO

Samir Patel (55 yo)

less than a year

Mandato

US$9,807

Compensazione

Dr. Samir Rashmikant Patel, M.D. served as an Independent Director of Akari Therapeutics, plc since November 29, 2023 until May 1, 2024 and also serves as its Interim President, Chief Executive Officer and...

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Samir Patel	Interim President	less than a year	US$9.81k	20.53% € 3.1m
Robert Bazemore	Director	less than a year	Nessun dato	Nessun dato
Donald Williams	Independent Director	8.4yrs	US$71.78k	0.084% € 12.5k
Raymond Prudo-Chlebosz	Chairman	9.2yrs	US$113.00k	15.3% € 2.3m
Mohamed Wa'el Hashad	Independent Director	1.4yrs	US$35.18k	0% € 0
Michael Grissinger	Independent Director	6.8yrs	US$66.85k	0.084% € 12.5k

4.1yrs

Durata media

64yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di CLA sono considerati esperti (durata media dell'incarico 4.1 anni).

Akari Therapeutics Gestione

Gestione criteri di controllo 2/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Akari Therapeutics, plc Appoints Samir R. Patel as Interim President

Akari Therapeutics, Plc, Annual General Meeting, Jun 27, 2024

Melissa Bradford-Klug to Step Down as Chief Operating Officer of Akari Therapeutics, Plc

Akari Therapeutics Appoints Samir R. Patel, M.D. to Board of Directors

Akari Therapeutics, Plc Announces Appointment of Beth-Anne Lang as Senior Vice President, Regulatory Affairs, Effective September 1, 2023

Akari Therapeutics, plc Announces Appointment of Wendy Dicicco as Interim Chief Financial Officer

Recent updates

Akari Therapeutics, Plc announced delayed 10-Q filing

Akari Therapeutics, Plc (NasdaqCM:AKTX) completed the acquisition of Peak Bio, Inc. (OTCPK:PKBO) from Pranabio Investments, Llc and others.

Akari Therapeutics Receives Delisting Determination Letter from Nasdaq Due to Failure to Meet the Terms of an Extension Granted by Nasdaq to Regain Compliance with the Stockholders’ Equity Requirement

Akari Therapeutics Receives Positive and Constructive Pre-IND Feedback from US FDA for PAS-nomacopan in Treatment of Geographic Atrophy

Akari Therapeutics, Plc announced delayed 10-Q filing

Akari Therapeutics, plc Appoints Samir R. Patel as Interim President

Akari Therapeutics, Plc, Annual General Meeting, Jun 27, 2024

Akari Therapeutics, Plc announced that it has received $0.5 million in funding

New major risk - Financial position

Melissa Bradford-Klug to Step Down as Chief Operating Officer of Akari Therapeutics, Plc

Akari Therapeutics Receives a Letter from the Listing Qualifications Staff of the Nasdaq Capital Market

New major risk - Share price stability

New major risk - Shareholder dilution

New major risk - Market cap size

New major risk - Negative shareholders equity

Akari Therapeutics, Plc (NasdaqCM:AKTX) entered into a definitive agreement to acquire Peak Bio, Inc. (OTCPK:PKBO).

Akari Therapeutics Appoints Samir R. Patel, M.D. to Board of Directors

Akari Therapeutics, Plc announced that it expects to receive $2 million in funding

Akari Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

Akari Therapeutics, Plc Announces Appointment of Beth-Anne Lang as Senior Vice President, Regulatory Affairs, Effective September 1, 2023

Akari Therapeutics, plc Grants Nomacopan Orphan Drug Designation from the European Commission for Treatment in Hematopoietic Stem Cell Transplantation

Akari Therapeutics, plc Announces Appointment of Wendy Dicicco as Interim Chief Financial Officer

Less than half of directors are independent

Akari Therapeutics Provides Updates on Development of Nomacopan in Pediatric and Adult HSCT-TMA

Akari Therapeutics, plc Announces Updates on the Development of Long-Acting Pas-Nomacopan as A Potential Treatment for Geographic Atrophy

Akari Therapeutics, plc Announces Management Appointments

Akari Therapeutics, Plc, Annual General Meeting, Jun 30, 2023

Akari Therapeutics, Plc Announces Pre-Clinical Development Progress Toward Potential IND on Long-Acting PAS-Nomacopan for Geographic Atrophy

Akari Therapeutics Announces Acceleration of the Phase 3 Clinical Trial of Nomacopan for Treatment of Pediatric Hsct-Tma into Pivotal Part B and Addition of A New Pipeline Program Developing Nomacopan for Hsct-Tma in Adults

No longer forecast to breakeven

Insufficient new directors

Akari Therapeutics Granted FDA Rare Pediatric Disease Designation of nomacopan for the Treatment of Pediatric HSCT-TMA

Akari Therapeutics Announces the Appointment of John F. Neylan, III as Executive Vice President, Chief Medical Officer

Akari Therapeutics Announces Receipt of Nasdaq Minimum Bid Price Notification

Akari Therapeutics, plc Announces That It Is Prioritizing Two Pipeline Programs

Insufficient new directors

Akari Therapeutics Announces Positive Results from Recent Pre-Clinical Studies of Investigational PASylated Nomacopan That Support the Potential to Advance Research Toward IND/IMPD for Clinical Trials in Geographic Atrophy

Akari Therapeutics Announces First Patient to Complete Course of Treatment in the Phase Iii Part A Clinical Trial of Investigational Nomacopan in Pediatric Hematopoietic Stem Cell Transplant-Related Thrombotic Microangiopathy

Akari Therapeutics, Plc Appoints Melissa Bradford-Klug as Chief Operating Officer, Effective July 1, 2022

Akari Therapeutics, Plc, Annual General Meeting, Jun 30, 2022

Akari Therapeutics, Plc Presents Results from the CASCADE and CORONET Studies in COVID-19

Akari Therapeutics Announces Publication of Phase II Data of Investigational Nomacopan for the Treatment of Bullous Pemphigoid (BP) in JAMA Dermatology

Akari Therapeutics, Plc Presents Positive Results from Two Preclinical Studies of Its Lead Asset, Investigational Nomacopan

Insufficient new directors

Akari Therapeutics, Plc Appoints Rachelle Jacques as President and Join its Board of Directors

Akari Therapeutics, Plc Appoints Rachelle Jacques as President and Join its Board of Directors

Akari Therapeutics, plc Announces New Data Showing That Clinical Outcomes in U.S. Army Trauma Patients Correlate with Complement Activation

Akari Therapeutics, plc Announces Advances Lung Program with Inhaled Nomacopan Focused on Early Treatment of Severe Exacerbations in Lung Diseases

Akari Therapeutics, Plc announces FDA Agrees to Use of New Higher-Yielding Manufacturing Process for Nomacopan in Pivotal Clinical Studies

Akari Therapeutics, Plc Presents New Data Revealing Potential Mechanism of Action Driving Serious Exacerbations Across Lung Disorders

Akari Therapeutics Receives FDA Fast Track Designation for Nomacopan for the Treatment of Bullous Pemphigoid

Akari Therapeutics, Plc Announces a Cooperative Research and Development Agreement with the U.S. Army Institute of Surgical Research for Nomacopan in Trauma

Akari Therapeutics Presents New Preclinical Data Highlighting Potential of Long-Acting PASylated Nomacopan to Treat Retinal Diseases, Including Age-Related Macular Degeneration (AMD) and Uveitis

New 90-day high: €3.12

Akari Therapeutics Adds Histamine Inhibitor Votucalis to Pipeline to Treat Neuropathic Pain and Dermatological Disease

New 90-day high: €2.00

Akari Therapeutics, Plc Announces New Clinical Data that Show Long-Term Self-Administered Nomacopan is Well-Tolerated and Substantially Reduces Transfusion Dependence in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)

New 90-day high: €1.63

Akari Therapeutics Announces Publication in American Journal of Pathology Highlighting Potential of Nomacopan in Treatment of Uveitis and Retinal Disease

New 90-day low: €1.19

Akari Therapeutics Announces Further Clinical Trial Progress Using Nomacopan to Treat COVID-19 Pneumonia

Akari Therapeutics Announces Successful Scientific Advice Meeting with the European Medicines Agency Establishing a Clear Path in Both U.S. and Europe for a Pivotal Phase III Study of Nomacopan for Treatment of Bullous Pemphigoid

New 90-day low - €1.30

New 90-day low - €1.50

AMMINISTRATORE DELEGATO

Mandato

Compensazione

Membri del Consiglio di amministrazione

Durata media